Form 10-Q Nurix Therapeutics, Inc. For: Aug 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
October 15, 2024 6:19 AM EDTWells Fargo analyst Derek Archila reiterated an Overweight rating and $32.00 price target on Nurix (NASDAQ: NRIX)
The analyst comments "Thoughts on the stock. Shares are up +146% vs XBI's +10% YTD. While there is decent value priced in for NX-5948's oppty... More



